Current Affiliation Organization 【 display / non-display 】

Current Affiliation Organization 【 display / non-display 】

External Career 【 display / non-display 】

External Career 【 display / non-display 】

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia

  Ishikawa, C; Mori, N

  EUROPEAN JOURNAL OF HAEMATOLOGY ( European Journal of Haematology )    2024.04 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• Inhibitory effect of a neddylation blockade on HTLV-1-infected T cells <i>via</i> modulation of NF-κB, AP-1, and Akt signaling

  Ishikawa, C; Mori, N

  LEUKEMIA & LYMPHOMA ( Leukemia and Lymphoma )    1 - 11   2024.03 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.

  Ishikawa C, Mori N

  Medical oncology (Northwood, London, England)   40 ( 6 ) 172   2023.05 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.

  Ishikawa C, Mori N

  Investigational new drugs ( Investigational New Drugs )  40 ( 4 ) 718 - 727   2022.08 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells.

  Ishikawa C, Mori N

  Investigational new drugs ( Investigational New Drugs )  40 ( 2 ) 245 - 254   2022.04 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Human T cell leukemia virus type 1 (HTLV-1) is responsible for adult T cell leukemia (ATL); however, molecular and cellular mechanisms underlying HTLV-1-induced leukemogenesis are unclear. BCL6 oncogene is involved in cancer progression and a preferred target of anti-cancer treatments. Here, we aimed to evaluate BCL6 expression and the effects of BCL6 inhibitor (FX1) on HTLV-1-infected T cell lines. BCL6 expression was higher in HTLV-1-infected T cell lines than that in uninfected T cell lines. BCL6 was localized mostly in the nucleus. The virus oncoprotein Tax induced BCL6 mRNA expression in T cells, whereas BCL6 knockdown reduced HTLV-1-infected T cell proliferation; thus, confirmed the association of BCL6 with cancer progression. Further, FX1 efficiently inhibited the cell growth and survival of HTLV-1-infected T cell lines in a dose- and time-dependent manner. The decreased levels of cell cycle regulatory proteins (phosphorylated retinoblastoma protein, cyclin-dependent kinase 4, cyclin D2 and c-Myc) and the increased levels of BCL6 target proteins (p21, p27 and p53) showed that FX1 arrested cell cycle at the G1 phase. Apoptosis was induced concomitantly with Bak upregulation and downregulation of survivin, Bcl-xL and Mcl-1, as well as with the activation of caspase-3, -8, -9 and poly(ADP-ribose) polymerase. FX1 also inhibited NF-κB and Akt signaling pathways. These events were because of the induction of the activity of cell cycle checkpoint proteins and relief of direct repression of the targets of cell cycle checkpoint proteins. Thus, BCL6 might be considered a novel target for ATL treatment.

  • Access this article
    DOI
  • Search related information
    PubMed

display all >>

Books 【 display / non-display 】

Books 【 display / non-display 】

• Mechanisms of cancer formation under interplay between host immunity and human papillomavirus (HPV) infection

  Senba M, Mori N ( Part: Multiple Authorship )

  Nova Science Publishers  2016

• Challenge to the threat of invisible transmission: global health security for the control of emerging infectious diseases outbreaks

  Senba M, Mori N ( Part: Multiple Authorship )

  Nova Science Publishers  2016

• Mechanisms of cancer formation under interplay between host immunity and human papillomavirus (HPV) infection

  Senba M, Mori N ( Part: Single Author )

  Nova Science Publishers  2016

• Challenge to the threat of invisible transmission: global health security for the control of emerging infectious diseases outbreaks

  ( Part: Single Author )

  2016

• Challenge to the threat of invisible transmission: Global health security for the control of emerging infectious disease outbreaks

  Senba M, Mori N ( Part: Single Author )

  Nova Science Publishers  2016

display all >>

Other Papers 【 display / non-display 】

Other Papers 【 display / non-display 】

• MALT1 as a novel therapeutic target for adult T-cell leukemia

      S161   2019.10

   

• 新規PI3K/HDAC二重阻害剤CUDC-907は原発性体腔液性リンパ腫の複数の細胞生存シグナルを抑制する

  森直樹, 石川千恵

  第78回日本癌学会学術総会プログラム集     187   2019.09

   

• Evaluation of artesunate for the treatment of adult T‐cell leukemia

  Naoki Mori, Chie Ishikawa

  臨床血液   59 ( 9 ) 1720 - 1720   2018.09

   

  J-GLOBAL

• アルテスネイトの原発性体腔液性リンパ腫に対する治療効果

  石川千恵, 森直樹

  第77回日本癌学会学術総会プログラム集 ( 日本癌学会 )    124   2018.09

   

  J-GLOBAL

• ATL治療薬としての新規PI3K/HDAC二重阻害剤CUDC-907

  森直樹, 石川千恵

  第77回日本癌学会学術総会プログラム集 ( 日本癌学会 )    71   2018.09

   

  J-GLOBAL

display all >>

Grant-in-Aid for Scientific Research 【 display / non-display 】

Grant-in-Aid for Scientific Research 【 display / non-display 】

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2013.04  -  2016.03 

  Direct: 3,900,000 (YEN)  Overheads: 1,170,000 (YEN)  Total: 5,070,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2009.04  -  2011.03 

  Direct: 2,600,000 (YEN)  Overheads: 780,000 (YEN)  Total: 3,380,000 (YEN)

• Grant-in-Aid for Scientific Research on Priority Areas

  Project Year: 2008.04  -  2010.03 

  Direct: 10,600,000 (YEN)  Overheads: 3,180,000 (YEN)  Total: 13,780,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2007.04  -  2009.03 

  Direct: 3,500,000 (YEN)  Overheads: 1,050,000 (YEN)  Total: 4,550,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2004.04  -  2006.03 

  Direct: 3,600,000 (YEN)  Overheads: 1,080,000 (YEN)  Total: 4,680,000 (YEN)

display all >>